Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

LONDON , Aug. 4, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces that the OXINIUM Technology Tour of Change mobile exhibit will make a stop at the Pro Football Hall of Fame during its enshrinement weekend in Canton, Ohio from August 4-6. As the official joint replacement technology of the Pro Football Hall of Fame, Smith+Nephew is committed to educating retired players, their families, and the community about the differences in material, design and technology to consider when selecting a hip or knee replacement.

Smith+Nephew's OXINIUM™ Technology Tour of Change touches down at the Pro Football Hall of Fame during enshrinement weekend

Smith & Nephew plc (NYSE:SNN ) Q2 2022 Results Conference Call July 28, 2022 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Julien Dormois - BNP Paribas Chris Gretler - Credit Suisse David Adlington - JP Morgan Deepak Nath I'll just draw your attention to the safe harbor statement on the slide that's about to pop up in front of us. So, it's a pleasure to be reporting the results of my first full quarter as CEO and also to be meeting many of you in person for the first time.

Smith & Nephew plc (SNN) CEO Deepak Nath on Q2 2022 Results - Earnings Call Transcript

Shares in Smith & Nephew PLC (LSE:SN) plunged almost 10% after forecasting a drop in profit margins on the back of inflation and “external supply challenges". The British medical products maker now expects trading profit margin of 17.5% for 2022 compared to a 18% margin last year.

Smith & Nephew's shares slump as profit margins squeezed

LONDON , July 13, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN) (NYSE: SNN), the global medical technology company, today announces a robust line-up featuring several of its advanced joint repair solutions and a wide array of educational activities during the 2022 American Orthopaedic Society for Sport Medicine (AOSSM) Annual Meeting being held in Colorado Springs July 13-17. These include: The REGENETEN◊ Bioinductive Implant With the potential to address approximately 17 million people with rotator cuff disease in the US1, the REGENETEN implant provides a patient centric treatment that supports the body's natural healing response required to facilitate healing of rotator cuff tears.2-6  With 20+ publications7 to its name, among the most in its category, the REGENETEN implant has been shown in early studies to disrupt disease progression3-5,8, expedite return to normal activity8 and potentially reduce re-tears.9,10 The REGENETEN implant is part of Smith+Nephew's comprehensive Advanced Healing Solutions portfolio - redefining biological healing in rotator cuff repair along with expanded applications for Gluteus Medius and Achilles tears.

Smith+Nephew to showcase latest innovations for sports medicine joint repair at 2022 AOSSM Annual Meeting

LONDON , July 12, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the WOUND COMPASS™ Clinical Support App. The WOUND COMPASS Clinical Support App is a comprehensive digital support tool for health care professionals that aids wound assessment and decision-making to help reduce practice variation.

Smith+Nephew launches Clinical Support App to help reduce practice variation in wound care

LONDON , June 30, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN), (NYSE: SNN), the global medical technology company, today announces the first robotic-assisted surgery using its LEGION CONCELOC Cementless Total Knee System was performed by Dr. Cyna Khalily, an orthopaedic surgeon specializing in adult reconstructive surgery of the hip and knee in Louisville, KY. Smith+Nephew is the only medical device company to offer both total and partial cementless knee implants, and now, a robotic-assisted solution for cementless total knee arthroplasty (TKA) with the CORI◊ Surgical System.

Smith+Nephew announces first robotic-assisted surgery using its LEGION™ CONCELOC™ Cementless Total Knee System

LONDON , June 14, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a new peer-reviewed article in Wounds International . The article proposes that an estimated 3.5 billion hours of nursing time could be released globally by 2030 if shared care approaches between nurses and patients are adopted in chronic wound care alongside long-wear advanced foam dressings1.

SMITH+NEPHEW SHARES NEW RESEARCH THAT ESTIMATES 3.5 BILLION HOURS OF NURSE TIME COULD BE RELEASED BY 2030 THROUGH SHARED WOUND CARE AND USE OF LONG-WEAR ADVANCED FOAM DRESSINGS

LONDON , June 8, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces that the first total hip arthroplasty (THA) procedure using RI.HIP MODELER, a new preoperative spinopelvic assessment tool, was performed by Dr. Rhett Hallows at Duke Regional Hospital. Separately, Dr. Thorsten Seyler performed the first-ever RI.HIP NAVIGATION procedure on the CORI Surgical System at Duke University in April.

Smith+Nephew announces first total hip replacement cases on its CORI™ Surgical System using RI.HIP MODELER and RI.HIP NAVIGATION

Oxford BioMedica PLC (AIM:OXB), Smith & Nephew PLC (LSE:SN) and Spire Healthcare Group Plc (LSE:SPI) are among UK midcap health-care companies 'vulnerable” to takeovers from private-equity (PE) firms, investment bank RBC Group says. The stocks trade below historical multiples and have under-geared balance sheets - making them ripe for "PE firms seemingly well-funded and large trade players having strong balance sheets, and in some cases post-COVID earnings holes to fill," according to the bank.

Oxford Biomedica, Smith & Nephew 'vulnerable' to takeover

LUGANO, Switzerland--(BUSINESS WIRE)-- #celltherapy--Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & al

Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

Smith & Nephew has seen its business performance turn the corner post-pandemic and I expect future growth. The share price has crept up slightly but I continue to see long-term value here.

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Smith & Nephew PLC (NYSE: SNN) posted Q1 revenue of $1.31 billion, up 3.3% on a reported basis (including -2.6% currency effect) and up 5.9% on an underlying basis. Sports Medicine & ENT revenue up 8.6% underlying.

Smith & Nephew Posts Q1 Sales Growth As Elective Procedures Rebound

Smith & Nephew PLC (LSE:SN) (Smith & Nephew PLC (LSE:SN)) said a recovery in elective surgery and good sports demand would keep it on track to hit its targets in 2022. Revenue in the first quarter rose 3.3% on a reported basis to US$1.3bn for the quarter ended April 2, up from US$1.26bn a year ago.

Smith & Nephew revenues jump as elective procedure volumes rebound

LONDON , March 31, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a peer-reviewed study in the Advances in Wound Care Journal reporting outcomes for Medicare patients with a diabetic foot ulcer (DFU) that shows GRAFIX Cryopreserved Placental Membrane cut DFU recurrence rates in half compared to leading cellular and tissue-based product (CTP) competitors.1 ( Link to publication ). DFUs affect 3 million people annually in the US, and Medicare spending for the treatment of DFUs has been estimated to be $6-18 billion annually.2 This study reviewed over 1.3 million Medicare patients with lower limb chronic ulcers, and analyzed 7,849 claims for patients treated between 2013 and 2017 in an outpatient setting who presented with a DFU and received a CTP.

Smith+Nephew announces new study showing GRAFIX™ Membrane cut the rate of diabetic foot ulcer recurrence in half compared to leading competitors

LONDON , March 22, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will it showcase its latest innovations for Orthopaedic Reconstruction and Robotics during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL. Introducing the Smith+Nephew Cementless Knee Continuum of Care Cementless knee implants are serving a resurgent segment1 driven by the potential for better long-term fixation through biologic integration2,3, shorter operating times4, and the shift to Ambulatory Surgery Centers (ASCs).5 Smith+Nephew is now the only company in the US with a cementless commercial offering for total knees with the recent launch of the LEGION™ CONCELOC™ Cementless Total Knee System - and partial knees with the acquisition of Engage Surgical and the ENGAGE ™ Cementless Partial Knee System earlier this year.

Smith+Nephew to showcase latest Orthopaedic advancements in Cementless Knees, Total Hip Arthroplasty and Robotics at AAOS 2022 Annual Meeting

LONDON , March 21, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL. The latest technologies include: FAST-FIX™ FLEX Meniscal Repair System: A surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus.1-3 Improving access leads to a greater opportunity to repair the meniscus rather than remove it, which can result in long-term benefits to the patient.4-6 INTELLIO™ Connected Tower: Brings together Smith+Nephew's leading capital technologies across its INTELLIO IMAGING, INTELLIO RESECTION and INTELLIO FLUID & ACCESS portfolios to deliver the "Power of Unity" to customers.

Smith+Nephew to feature Sports Medicine technology for joint repair and connected arthroscopic tower during AAOS 2022 Annual Meeting

LONDON, March 15, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces it has kicked-off the OXINIUM Technology Tour of Change mobile exhibit. OXINIUM (Oxidized Zirconium) Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA) at 9-17 years1-4, with strong clinical performance in knees.5,6 The Tour of Change is a 550 square foot mobile exhibit that will visit leading Orthopaedic centers in approximately 20 U.S. cities over 12 weeks.

Smith+Nephew embarks on the OXINIUM™ Technology Tour of Change; a mobile learning exhibit to showcase the best performing bearing for total hip arthroplasty

Surging commodity prices lifted London stocks to positive territory on Tuesday, as geopolitical tensions swirled around investors.

London Markets: Hargreaves Lansdown shares slump, while Smith & Nephew soar as U.K. stocks grapple with geopolitics

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q4 2021 Results - Earnings Call Transcript

Smith & Nephew PLC (LSE:SN) said pre-tax profit more than doubled in 2021, helped by strong sales in its sports medicine & ENT and wound care segments, all of which delivered revenue higher than in pre-Coronavirus (COVID-19) 2019. The medical group also revealed Dr Deepak Nath was appointed as the new chief executive officer (CEO), succeeding Roland Diggelmann, who will step down by mutual agreement.

Smith & Nephew FY operating profits double; CEO to depart

LONDON, Feb. 10, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the first completed surgery using its JOURNEY II Medial Dished (MD) System for total knee arthroplasty (TKA). The procedure was performed by Dr. Ran Schwarzkopf, Orthopedic Adult Hip and Knee Reconstruction at NYU Langone Health.

Smith+Nephew announces first surgery for its JOURNEY™ II Medial Dished System for total knee arthroplasty

Smith+Nephew's (SNN) acquisition of Engage Surgical reinforces its growth strategy while expanding its Orthopaedic Reconstruction product line.

Smith+Nephew (SNN) to Acquire Orlando-Based Engage Surgical

Medical devices manufacturer continues to suffer from lower demand than pre-pandemic, but recovery is in progress. The company has set out a growth plan but I don't find it persuasive.

Smith & Nephew: Valuation Looking More Attractive

LONDON, Jan. 26, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the expansion of indications on its CORI Surgical System - the industry's most advanced and efficient1,* handheld robotic solution in total knee arthroplasty1,*,† - to now include total hip arthroplasty (THA). Smith+Nephew's RI.HIP NAVIGATION - designed to help maximize accuracy and reproducibility by delivering patient-specific component alignment for THA – is now available for use on its CORI System.

Smith+Nephew expands next-generation handheld robotic-assisted CORI™ Surgical System into total hip arthroplasty with RI.HIP NAVIGATION

LONDON, Jan. 24, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce new indications for use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy (sNPWT) Systems. The U.S. Food and Drug Administration (FDA) cleared the systems for use on  closed surgical incisions, to aid in reducing the incidence of: Superficial and deep incisional surgical site infections (SSIs) for high risk patients in Class I and Class II wounds Post-operative seroma Dehiscence The development of post-operative surgical site complications (SSCs), such as surgical wound dehiscence, are a substantial burden for patients and healthcare systems, globally1.

Smith+Nephew's PICO™ 7 and PICO 14 Negative Pressure Wound Therapy Systems are the first systems indicated to aid in reducing the incidence of both deep and superficial incisional surgical site infections and dehiscence

News for Smith & Nephew Stock (SNN)